CSPC innovation pharmaceutical reports returns from cash management activities

CSPC Innovation Pharmaceutical has disclosed the progress of its cash management activities, utilizing idle raised funds as approved by its shareholders. The company’s board of directors and supervisory board, along with independent directors and the sponsor institution, approved the use of up to RMB 800 million in idle raised funds for cash management through principal-protected products with high safety and liquidity, such as structured deposits and large-denomination certificates of deposit. This strategy aims to enhance efficiency and increase investment income without affecting the construction of its investment projects or normal operations.

Several cash management products have recently matured and been redeemed. Two such products from China Everbright Bank, each with a principal of RMB 14,000.00, matured on December 12, 2025, yielding RMB 54.25 in profit respectively. The company noted that it continues to deploy temporarily idle raised funds for new cash management products.

As of the announcement date, the total amount of idle raised funds currently under cash management and yet to mature stands at RMB 38,500.00. The company affirms that these cash management activities adhere to internal approval procedures and are within the approved limits and duration. The investment strategy prioritizes security and liquidity while contributing to the company’s overall financial performance.